Target intelligence / Profile preview

Ribosomal L1 domain-containing protein 1 (RSL1D1)

Target
RSL1D1
Molecular classification
RNA-binding protein, Ribosomal protein (contains ribosomal L1 domain; member of universal ribosomal protein uL1 family), Transcriptional cofactor, Other (nucleolar protein)
01

Overview

Ribosomal L1 domain-containing protein 1 (RSL1D1) is a nucleolar RNA-binding protein that participates in multiple cellular processes, including cell cycle progression, regulation of cellular senescence, rRNA processing, and apoptosis. It contains an N-terminal ribosomal L1 domain and a lysine-rich C-terminal domain. RSL1D1 is highly expressed in proliferating cells and various cancers, and its expression declines during cellular senescence. Functionally, it promotes cell proliferation by negatively regulating PTEN translation, interacts with c-Myc to prevent its ubiquitination, and suppresses autophagy by interacting with RAN, influencing STAT3 nuclear distribution. RSL1D1 also modulates the p53 pathway by stabilizing HDM2 mRNA and recruiting p53 for degradation, leading to reduced p53 levels and enhanced cancer cell survival. RSL1D1's activity is implicated in the progression, invasion, and metastasis of colorectal and other cancers and its high expression is a poor prognostic marker in these contexts.

Other names
Cellular senescence-inhibited gene protein (CSIG)CATX11PBK1L12DKFZP564M182UTP30CATX-11Protein PBK1Ribosomal L1 domain-containing protein 1CSIG
02

Mechanism of action

no therapeutics directly acting via RSL1D1 currently described; functional mechanisms for the protein itself include suppression of PTEN translation, modulation of p53 ubiquitination via HDM2, interaction with c-Myc, suppression of autophagy through RAN/Sirt7 competition

03

Biological functions

Regulation of cellular senescenceCell proliferationCell cycle progressionRegulation of apoptosis (pro-apoptotic in DNA damage response)Regulation of autophagyrRNA processingRegulation of protein localizationmRNA 3'-UTR and 5'-UTR binding (PTEN, NOLC1)
04

Disease associations

Cancer (colorectal cancer, hepatocellular carcinoma, prostate, breast cancer)Bowen-Conradi SyndromeOther: Aging/Cellular senescence (expression declines with senescence in fibroblasts)
05

Safety considerations

no direct safety or toxicity data available; therapeutic challenges may relate to complex role in cell proliferation and apoptosis regulation
06

Biomarkers

High expression of RSL1D1 in tumor tissue correlates with poor prognosis in colorectal cancer

Beyond the preview

Go deeper on Ribosomal L1 domain-containing protein 1 (RSL1D1).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Ribosomal L1 domain-containing protein 1 (RSL1D1).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call